Table I.
Baseline characteristics.
| Characteristic | No. |
|---|---|
| Median age, years (range) | 65 (34–81) |
| Gender | |
| Female | 7 |
| Male | 10 |
| Performance status (ECOG) | |
| 0 | 5 |
| 1 | 12 |
| Prior chemotherapy | |
| 1 prior chemotherapy regimen | 7 |
| 2 prior chemotherapy regimens | 10 |
| High dose/ASCT | 5 |
| Rituximab | 16 |
| Prior radiotherapy | 8 |
| Best response to last chemotherapy | |
| Unknown | 1 |
| Complete response | 7 |
| Partial response | 3 |
| Stable disease | 3 |
| Progressive disease | 2 |
| Inevaluable | 1 |
| Number of sites of disease | |
| 1 | 5 |
| 2 | 3 |
| 3 | 3 |
| 4 (or more) | 6 |
| Histology | |
| DLBCL | 14 |
| PMBCL | 1 |
| Transformed diffuse large B-cell | 2 |
| Baseline LDH | |
| ≤ULN | 6 |
| >41–2.5 × ULN | 4 |
| >42.5–5 × ULN | 3 |
| >45 × ULN | 4 |
ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell transplant; DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; LDH, lactate dehydrogenase; ULN, upper limit of normal.